It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The one-time treatment involves collecting the patient’s own T cells, white blood cells key to the immune system, and genetically changing them in the lab so that they will find and attack cancer cells. The modified cells are given back to the patient through IV.
Over time, researchers said, the modified cells evolved, many turning into “helper” cells that work with the cancer-killing cells. Helper cells eventually became dominant in both patients.
Study author J. Joseph Melenhorst said they were able to isolate and analyze the cells using new technologies, which gave them “very good insight” into how they persisted in the patients’ bodies.
Dr. Armin Ghobadi of Washington University in St. Louis, an expert in gene and cellular immunotherapy for cancer, called the findings “incredible.” Though the word “cure” is rarely used in cancer, he said it appears these patients were “most likely” cured.
The one-time treatment involves collecting the patient’s own T cells, white blood cells key to the immune system, and genetically changing them in the lab so that they will find and attack cancer cells. The modified cells are given back to the patient through IV.
Our engineered cell therapies express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. This dual platform has the potential to transform cancer treatment by addressing the goal of treating both hematological cancers and solid tumors.
Our research and development efforts are focused on engineered allogeneic cell therapies with a scalable technology platform to increase therapeutic options and availability for patients.
Ivermectin has powerful antitumor effects, including the inhibition of proliferation, metastasis, and angiogenic activity, in a variety of cancer cells. This may be related to the regulation of multiple signaling pathways by ivermectin through PAK1 kinase. On the other hand, ivermectin promotes programmed cancer cell death, including apoptosis, autophagy and pyroptosis. Ivermectin induces apoptosis and autophagy is mutually regulated. Interestingly, ivermectin can also inhibit tumor stem cells and reverse multidrug resistance and exerts the optimal effect when used in combination with other chemotherapy drugs.
originally posted by: Sookiechacha
a reply to: scraedtosleep
The tech has been around for awhile now, but it's quite expensive. Therapy is done in a series of treatments, and the cost is around $40K per treatment. Pretty sure Medicare doesn't cover it....
originally posted by: Sookiechacha
a reply to: WhiteHat
You might be able to hook up your mom in some clinical trial program. I know Appia Bio is expecting to start trials sometime in the near future. I'm sure there are other Bio-techs out there working on cancer CAR-T Therapies.
www.clinicalconnection.com...
originally posted by: scraedtosleep
The one-time treatment involves collecting the patient’s own T cells, white blood cells key to the immune system, and genetically changing them in the lab so that they will find and attack cancer cells. The modified cells are given back to the patient through IV.
originally posted by: MapMistress
All one would need to do is to take a sample of memory t-cells from those with natural immunity to cancer and give them as a serum to a cancer patient. Once the serum is injected, the person with cancer would acquire the memory t-cells that fight cancer and those cells would teach their cells.